Expression and pharmacological evaluation of fusion protein FGF21-L-Fc.
- Author:
Wenbing YAO
;
Guiping REN
;
Yang HAN
;
Hongwei CAO
;
Hongmei GAO
;
Fangming KAN
;
Qi WANG
;
Deshan LI
- Publication Type:Journal Article
- From:
Acta Pharmaceutica Sinica
2011;46(7):787-92
- CountryChina
- Language:Chinese
-
Abstract:
FGF21 (fibroblast growth factor 21) is a recently described member of the FGF family. It has been previously demonstrated that FGF21 is a potent regulator of glucose homeostasis. To improve stability of FGF21 for better efficacy, a new form of recombinant FGF21 was generated by fusion of a full length FGF21 gene and the Fc fragment of human IgG4 with flexible linker sequence. To examine the glucose regulation activity of FGF21-L-Fc, 3T3-L1 pre-adipocytes were differentiated into adipocytes, and glucose uptake activity of FGF21-L-Fc was examined by glucose oxidase and peroxidase (GOD-POD) assay. The results showed that in comparison with wild type FGF21, FGF21-L-Fc was more potent in stimulation of glucose uptake by 3T3-L1. In vivo studies on the modified protein demonstrated that FGF-L-Fc had a better efficacy in lowering blood glucose of the STZ-induced diabetic animals and controlled glucose level for a longer time. The results provided a sound basis for further studies.